Type private Founder David R. Liu | Website permeonbio.com Founded 2011 | |
Industry Health care
Biotechnology Headquarters Cambridge, Massachusetts, United States Key people John Ripple
Noubar Afeyan Products Intraphilin™ Technology Platform | ||
Permeon Biologics, Inc. is a privately held pharmaceutical and biotechnology company in Cambridge, Massachusetts. Founded in 2011 by Harvard chemist David R. Liu and Noubar Afeyan, CEO of Flagship Ventures, the company’s develops a class of proteins, under the trademark Intraphilin™, that enable the transport of large molecules such as antibodies into cells, thereby potentially enabling new classes of intracellular therapies.
Ownership
Permeon Biologics closed a Series A financing in November, 2010, with Flagship Ventures of Cambridge, Massachusetts, and ARCH Venture Partners of Chicago.
References
Permeon Biologics Wikipedia(Text) CC BY-SA